Total
0
Shares
Kalytera Therapeutics receives positive results from drug study
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PharmaDrug (BUZZ) has entered into a service agreement with a respected contract research organization to study the company's formulation of Cepharanthine (PD-001) as a cancer treatment
  • The company's current study will examine the anti-cancer properties of PD-001
  • A planned follow-up study will examine the benefit of PD-001 alone or when combined with relevant first and second-line chemotherapy drugs
  • Compared to generic Cepharanthine, PD-001 has been shown to be more easily absorbed, supporting the development of an orally administered formulation
  • PharmaDrug is a specialty pharmaceutical company focused on the development of controlled substances and natural medicines
  • Pharmadrug Inc. is up 5.56 per cent, trading at C$0.095 per share at 1:45 pm ET

PharmaDrug (BUZZ) has entered into a service agreement with a respected contract research organization (CRO).

PharmaDrug and the CRO will jointly evaluate the company's patented enteric-coated formulation of Cepharanthine ("PD-001") in a broad panel of human cancers.

"We are focused on advancing the clinical development of our novel Cepharanthine formulation that not only has significant potential for infectious diseases, but also in select rare forms of cancer with high unmet medical needs," said Daniel Cohen, CEO of PharmaDrug.

"Our research and development strategy to identify highly probable uses of PD-001 in select cancer indications will allow us to de-risk and accelerate development of preclinical and clinical studies while building core competencies and scientific data for future partnering opportunities with pharmaceutical companies."

Based on multiple, positive preclinical data sets and a recent decision from the FDA to grant Orphan Drug Designation (ODD) for Cepharanthine in the treatment of esophageal cancer, PharmaDrug remains committed to fully exploring this clinical opportunity.

PharmaDrug will also undertake efforts to confirm and expand on Cepharanthine's noted benefit in previously examined cancers, while also assessing potential benefit across a panel of untested cancer types.

The company's current study, which will examine the anti-cancer properties of PD-001 in a large panel of solid and liquid cancer cell types, will be conducted under study conditions that will facilitate valid head-to-head comparisons of relative drug potency.

A planned follow-up study will use data generated from the first study to examine the benefit of PD-001 alone (monotherapy) or when combined with relevant first and second-line chemotherapy drugs.

In most cases, the adoption of any novel anti-cancer therapeutic occurs as an 'add-on' to an established multidrug standard of care. The development of chemoresistance after repeated and prolonged exposure to chemotherapy remains a significant clinical challenge. Cepharanthine has been shown in preclinical efficacy models to restore cancer cell sensitivity to multiple unrelated classes of chemotherapy.

Collectively, the studies being undertaken by PharmaDrug aim to identify and provide focus on new opportunities in oncology by revealing optimal drug combinations, situations where PD-001 can prevent, lessen, or reverse chemoresistance, and/or provide additive/synergistic benefit to existing treatments.

Data collected during these studies will be used to help inform the company's downstream clinical development efforts while also potentially creating opportunities to secure additional intellectual property around any novel findings.

Cepharanthine is a natural product and an approved drug that has been used for more than 70 years in Japan to successfully treat a variety of acute and chronic diseases. In clinical research, Cepharanthine has been shown to exhibit multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. However, historically Cepharanthine's low oral bioavailability has represented a major obstacle to realizing its full clinical potential.

PharmaDrug is focused on advancing the clinical development of an improved oral formulation of Cepharanthine (PD-001) to treat rare cancers and infectious diseases.

Compared to generic Cepharanthine, PD-001 has been shown in rodent and non-rodent models to possess markedly superior bioavailability (more easily absorbed). These findings support the development of an orally administered formulation, and in so doing, removes the undesirable requirement for frequent intravenous dosing.

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs.

Pharmadrug Inc. is up 5.56 per cent, trading at C$0.095 per share at 1:45 pm ET.

More From The Market Herald
Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

" Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market.
Levitee Labs - CEO, Pouya Farmand. - The Market Herald Canada

" Levitee Labs (CSE:LVT) announces DTC eligibility

Common shares of Levitee Labs (LVT) are now eligible to be electronically cleared and settled through the DTC.
Avicanna Inc - CEO, Aras Azadian - The Market Herald Canada

" Avicanna (TSX:AVCN) files US patent application for cannabinoid formulation

Avicanna (AVCN) has filed a provisional patent application with the United States Patent and Trademark Office.
Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

" Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

Alpha Cognition (ACOG) has announced a C$12.5 million public offering led by Raymond James.